Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. SPRAVATO® carries a Boxed Warning regarding a Risk Evaluation and Mitigation Strategy (REMS) and the risk of suicidal thoughts...

READ MORE Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

Too poor to buy, too scared to meet: Palestinians face joyless Ramadan

Local Journalism Initiative Christmas is coming in Canada’s smallest town[1] The Christmas season is marked by a couple of things.  Usually, that includes the decorating of homes inside and out with lights, Santas, Christmas trees and other holiday-themed items.  Every December, the holiday season unfolds in Tilt Cove the same as it does in St. John’s, Mount Pearl and Labrador...

READ MORE Too poor to buy, too scared to meet: Palestinians face joyless Ramadan

Insights into the Worldwide Antidepressants Industry to 2030 – Identify Growth Segments for Investment

DUBLIN–(BUSINESS WIRE[1])–The “Antidepressants Global Market Report 2020-30: COVID 19 Implications and Growth”[2] report has been added to ResearchAndMarkets.com’s offering. The global antidepressants market is expected to grow from $14.3 billion in 2019 to about $28.6 billion in 2020 as mental health issues are expected to surge due to the effects of the COVID-19 pandemic making an impact on the global...

READ MORE Insights into the Worldwide Antidepressants Industry to 2030 – Identify Growth Segments for Investment

Sage redraws its plans for failed antidepressant drug

Dive Brief: Sage Therapeutics will start three new clinical trials of its experimental antidepressant zuranolone in an attempt to forge a path forward for the drug after a disappointing study setback[1] three months ago. That failed study, called MOUNTATIN, was intended to support an application for approval to the Food and Drug Administration. Without it, Sage has been forced to...

READ MORE Sage redraws its plans for failed antidepressant drug

Generated by Feedzy